Galderma Launches Alastin ® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market
Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare markets.6-8 This is the first launch to feature Alastin by Galderma’s new re-energized, premium look and feel, a bold evolution that reflects its leadership in perioperative skincare.
Alastin offers full-spectrum care for patients undergoing aesthetic procedures, from pre-treatment preparation to post-treatment recovery and at-home maintenance, supporting the skin’s natural regenerative abilities to improve overall skincare results.1,2,9-13 With over 50 global dermatological publications and 22 patents, Alastin is strongly backed by science and is the number one peri-procedural skincare brand in the United States.14-16 This launch follows the strong growth of Alastin in other key markets and demonstrates Galderma’s commitment to addressing the needs of patients with science-backed solutions.
“With Alastin by Galderma, we have a comprehensive perioperative solution to enhance skin recovery around aesthetic treatment and maintenance programs that bring together Galderma’s leading expertise in Dermatological Skincare and Injectable Aesthetics. As the Asia-Pacific region’s beauty and aesthetics market continues to grow at pace, we’re proud to bring Alastin to patients in China who are seeking advanced solutions to support them in their aesthetic journeys.”
|
Comprehensive perioperative solutions addressing growing needs
Four core Alastin products that cover all stages of the aesthetic treatment process will now be available in China, creating an integrated in-clinic and at-home skincare program:
- Regenerating Skin Nectar to optimize visible treatment results9
- HA (Hyaluronic Acid) IMMERSE Serum™ to hydrate and support skin barrier repair10
- INhance Serum helps to enable quicker recovery after treatment with injectables, improving the appearance of the skin post-injection11
- Restorative Skin Complex to support aesthetic treatment results by helping to reduce the visible signs of aging12
This comprehensive perioperative series of regenerative skincare products advances aesthetic treatments from isolated procedures to full-spectrum management.1,2,9-12 It reflects Galderma’s holistic approach to aesthetic care – working across its Dermatological Skincare and Injectable Aesthetics portfolios to ensure that products complement each other, delivering seamless, science-backed solutions that elevate patient outcomes.1,2,9-13 Select products are powered by proprietary TriHex Technology® to further enhance skin regeneration and recovery.1,2,13
China’s medical aesthetics market is experiencing remarkable growth, and is projected to increase by up to 15% in the next decade.17 As aesthetic treatments become increasingly mainstream there is rising demand for perioperative skincare, with consumers willing to invest in advanced technologies and premium products to achieve optimal aesthetic outcomes.3-6,17 With its proven efficacy and full-spectrum approach to pre- and post-procedure care, as well as at-home maintenance, Alastin by Galderma is uniquely positioned to address this need.1,2,6-9
“We’re seeing an incredible rise in demand for aesthetic procedures in China, and with that comes a growing need for effective perioperative skincare. Alastin by Galderma brings a scientifically advanced approach to skin recovery, and I’m excited to see Chinese patients gain access to products that can truly support their skin before and after treatment, and elevate their overall results.”
|
This launch marks ten years of pioneering innovation with Alastin, demonstrating Galderma’s commitment to purposeful growth with the brand’s refreshed premium look and feel, and entry into one of the fastest growing aesthetic skincare markets. Following strong growth in North America, Latin America, Australia, and the U.K. & Ireland, Alastin is now undergoing rapid international expansion, offering its premium products to even more patients. By identifying emerging patient needs and delivering science-backed solutions, Galderma continues to shape the future of dermatology and elevate outcomes across the aesthetic journey.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References | |
1. | Widgerow AD, et al. Extracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures. J Drugs Dermaol. 2016;15(Suppl 4):s63–71. |
2. | Widgerow AD, et al. Preoperative Skin Conditioning: Extracellular Matrix Clearance and Skin Bed Preparation, A New Paradigm. Aesthetic Surgery Journal 2019;39(Suppl 3):s103–11. doi:10.1093/asj/sjz022 |
3. | Guidepoint Qsight. From Gen Z to GLP-1s: Trends Reshaping the Medical Aesthetics Industry. Accessed September 2025. Available online. |
4. | Verified Market Reports. Preoperative Skin Preparation Market. Accessed September 2025. Available online. |
5. | PW Consulting Health Care Research Center. Post Procedure Skin Care Product Market. Accessed September 2025. Available online. |
6. | Kwon SH, et al. Experiences and attitudes toward aesthetic procedures in East Asia: a cross-sectional survey of five geographical regions. Arch Plast Surg. 2021;48(6):660-669. doi: 10.5999/aps.2020.02565. |
7. | Fortune Business Insights. China Skincare Market Size, Share & Industry Analysis. Accessed September 2025. Available online. |
8. | Mordor Intelligence. China Cosmetic Products Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030). Accessed September 2025. Available online. |
9. | Alastin. Regenerating Skin Nectar with TriHex Technology®. Accessed September 2025. Available online. |
10. | Alastin. HA (Hyaluronic Acid) IMMERSE Serum™. Accessed September 2025. Available online. |
11. | Alastin. INhance Post-Injection Serum with TriHex Technology®. Accessed September 2025. Available online. |
12. | Alastin. Restorative Skin Complex with TriHex Technology®. Accessed September 2025. Available online. |
13. | Lee WW, et al. A Multi-Center Evaluation of Restorative Eye Treatment and INhance With Trihex Technology to Improve Aesthetic Outcomes When Used Pre- and Post-Blepharoplasty. Aesthet Surg J Open Forum. 2022 Dec 14;5:ojac089. doi: 10.1093/asjof/ojac089. |
14. | Galderma. Data on File. Alastin Publication List. |
15. | Galderma. Data on File. Alastin Patent List. |
16. | Galderma. Data on File. LifeSci Consulting Primary Market Research. 2022. |
17. | Chameleon Pharma. China’s Dynamic Aesthetic Medicine Market: Outlook, Trends, and Opportunities. Accessed September 2025. Available online. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909403223/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Expands Capabilities in Asia Pacific with VDB Loi10.9.2025 16:30:00 EEST | Press release
Andersen Consulting broadens its capabilities in Cambodia, Vietnam, and Laos as VDB Loi brings consulting capabilities to its existing tax and legal offering. Led by Managing Director Jean Loi, who also serves as managing director for Andersen in Cambodia and Vietnam, VDB Loi was founded in 2012 as a tax and legal firm and has been a collaborating firm of Andersen Global since 2021. With the addition of its full suite of consulting services, VDB Loi is now a member of Andersen Consulting offering comprehensive solutions in business strategy, AI, technology transformation, and cybersecurity to complement its existing tax and legal platform. “We have been a part of the Andersen family for several years now and recognize the value and synergy this multidisciplinary approach provides for our clients,” Jean said. “In our current business landscape, it is not enough to be solely a tax firm or solely a legal firm as a single service offering does not effectively cover clients’ overall busines
INNORNA Completes Phase II Enrollment and Vaccination of Bivalent RSV mRNA Vaccine IN00610.9.2025 16:21:00 EEST | Press release
Innorna today announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory syncytial virus (RSV) mRNA vaccine currently in development by the company. IN006 is also China's first domestically developed RSV vaccine to enter clinical trials, following IND approval in June 2024. The Phase I trial began with the first subject vaccinated in November 2024. Completion of enrollment and dosing in Phase II marks a milestone toward dose optimization and sets the stage for Phase III efficacy studies. The Phase II study is a randomized, double-blind, placebo-controlled trial conducted in China among healthy adults aged 60 and above. Key study objectives include dose optimization, broader population validation, and booster evaluation for annual revaccination. “This Phase II clinical trial marks a critical step in validating IN006’s scientific hypothesis—delivering broad-spectrum, durable protection against RSV,” said Dr. Lin
Xsolla Web Shop and Singular Join Forces to Deliver Cross-Platform LTV and ROAS Measurement Solutions10.9.2025 16:00:00 EEST | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Singular, a leading marketing analytics and attribution platform. The integration unifies mobile marketing data with direct-to-consumer web purchases, enabling developers to measure campaign performance and player value more accurately than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910813948/en/ Graphic: Xsolla As mobile game makers increasingly turn to Web Shops to expand revenue streams beyond app stores, one challenge has persisted: how to tie those off-platform transactions back to mobile marketing spend. The Xsolla Web Shop + Singular S2S integration closes this gap by treating Web Shop purchases as attributable events, giving developers true Return on Advertising Spend (ROAS) and comprehensive Lifetime Value (LTV) ins
Veritas Capital Closes Ninth Flagship Fund at Hard Cap of $14.4 Billion10.9.2025 16:00:00 EEST | Press release
Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government, today announced the final close of The Veritas Capital Fund IX (“Fund IX”) with $14.4 billion in aggregate capital commitments. Fund IX was significantly oversubscribed, with demand exceeding the hard cap and surpassing the initial target of $13 billion. The fundraise represents a 35% increase over Fund VIII which closed at $10.7 billion in 2022. With the close of Fund IX, Veritas now manages more than $54 billion in assets across its strategies, strengthening its position as a leading investor focused on technology. “Fund IX represents an important step forward for Veritas, and I’m deeply proud of our team and the enduring partnerships that made this milestone possible,” said Ramzi Musallam, Chief Executive Officer and Managing Partner of Veritas. “In one of the most challenging fundraising environments in recent memory, strong demand for Fund IX is a clear endorsement of our strategy and
INTRESO's New Fumigation Treatment Approved in U.S. as a High-Efficacy Alternative to the Damaging Methyl Bromide10.9.2025 16:00:00 EEST | Press release
International Treatment Solutions (INTRESO) Group is pleased to announce the registration of eFUME® by the U.S. Environmental Protection Agency (EPA). The registration marks an important milestone for the U.S. agricultural sector in safeguarding its supply chains and biosecurity. eFUME® is a fast-acting, safe, and effective solution for protecting post-harvest produce, packaged and stored foods, and processing equipment. Suited to a wide variety of fruits, vegetables, grains, and cut flowers, its active ingredient, ethyl formate, is a naturally occurring substance. It is regarded as safe for human health by the U.S. Food and Drug Administration (FDA), yet rapidly and effectively eliminates insect pests, typically within one to 24 hours, resulting in no withholding period and faster shipping. Designed for broad applications, eFUME® is effective against stored product insects, fresh produce pests, mites, quarantine pests of concern, and household insects. It is already registered and wid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom